Robert Belshe
Infectious Disease · Saint Louis, MONPI 1881700219
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $325,698 of the $381,600 with a category attached, or 85.4%. 6 manufacturers reported payments, led by Pfizer at 46.9% of the total. Reporting peaked in 2021 at $77,791 and has fallen 67.2% since, to $25,538 in 2025. Among infectious disease clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 181 payments — averaging $2108.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$179K
- GSK$89K
- Sanofi Pasteur Inc.$76K
- Merck$24K
- Dermira, Inc.$10K
- AstraZeneca$3K
Across 1 payment — averaging $5850.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$6K
What the payments were for
- Consulting fees$325,69885%
- Speaking & faculty fees$48,72013%
- Travel & lodging$5,9852%
- Food & beverage$1,1970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 58 | $179,025 |
| GSK | 26 | $89,424 |
| Sanofi Pasteur Inc. | 72 | $76,210 |
| Merck | 22 | $23,995 |
| Dermira, Inc. | 2 | $9,947 |
| AstraZeneca | 1 | $3,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COMIRNATY$59,063
- FLUZONE HIGH-DOSE$54,504
- FLUBLOK QUADRIVALENT$29,404
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE$25,146
- QBREXZA$9,947
- ENFLONSIA$1,110
- NO PRODUCT DISCUSSED$227
- FLUZONE QUADRIVALENT$110
How this compares
$381,600 in reported general payments places this provider in the 95th percentile of 177 infectious disease providers in Missouri.
Other infectious disease in Saint Louis
- Erik DubberkeSaint Louis$144K
- Rupa PatelSaint Louis$96K
- Michael DiamondSaint Louis$44K
- Andrej SpecSaint Louis$26K
- William PowderlySaint Louis$20K
- Elvin GengSaint Louis$15K
- Matifadza HlatshwayoSaint Louis$11K
- Bernard CaminsSaint Louis$11K
- Joseph CherabieSaint Louis$9K
- Rachel PrestiSaint Louis$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.